Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2014 Jun 19;9(6):e100497.
doi: 10.1371/journal.pone.0100497. eCollection 2014.

2012-2013 Seasonal influenza vaccine effectiveness against influenza hospitalizations: results from the global influenza hospital surveillance network

Joan Puig-Barberà  1 , Angels Natividad-Sancho  1 , Odile Launay  2 , Elena Burtseva  3 , Meral A Ciblak  4 , Anita Tormos  1 , Amparo Buigues-Vila  1 , Sergio Martínez-Úbeda  1 , Anna Sominina  5 ; GIHSN Group
Affiliations
Multicenter Study

2012-2013 Seasonal influenza vaccine effectiveness against influenza hospitalizations: results from the global influenza hospital surveillance network

Joan Puig-Barberà et al. PLoS One. .

Erratum in

  • PLoS One. 2014;9(9):e107849

Abstract

Background: The effectiveness of currently licensed vaccines against influenza has not been clearly established, especially among individuals at increased risk for complications from influenza. We used a test-negative approach to estimate influenza vaccine effectiveness (IVE) against hospitalization with laboratory-confirmed influenza based on data collected from the Global Influenza Hospital Surveillance Network (GIHSN).

Methods and findings: This was a multi-center, prospective, active surveillance, hospital-based epidemiological study during the 2012-2013 influenza season. Data were collected from hospitals participating in the GIHSN, including five in Spain, five in France, and four in the Russian Federation. Influenza was confirmed by reverse transcription-polymerase chain reaction. IVE against hospitalization for laboratory-confirmed influenza was estimated for adult patients targeted for vaccination and who were swabbed within 7 days of symptom onset. The overall adjusted IVE was 33% (95% confidence interval [CI], 11% to 49%). Point estimates of IVE were 23% (95% CI, -26% to 53%) for influenza A(H1N1)pdm09, 30% (95% CI, -37% to 64%) for influenza A(H3N2), and 43% (95% CI, 17% to 60%) for influenza B/Yamagata. IVE estimates were similar in subjects <65 and ≥65 years of age (35% [95% CI, -15% to 63%] vs.31% [95% CI, 4% to 51%]). Heterogeneity in site-specific IVE estimates was high (I2 = 63.4%) for A(H1N1)pdm09 in patients ≥65 years of age. IVE estimates for influenza B/Yamagata were homogenous (I2 = 0.0%).

Conclusions: These results, which were based on data collected from the GIHSN during the 2012-2013 influenza season, showed that influenza vaccines provided low to moderate protection against hospital admission with laboratory-confirmed influenza in adults targeted for influenza vaccination. In this population, IVE estimates against A(H1N1)pdm09 were sensitive to age group and study site. Influenza vaccination was moderately effective in preventing admissions with influenza B/Yamagata for all sites and age groups.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have read the journal's policy and we have the following conflicts: JPB works for the Vaccines Research Area of FISABIO, which has received funding from GlaxoSmithKline, Novartis, Pfizer, Sanofi Pasteur, and Sanofi Pasteur-MSD for conducting studies on infectious disease epidemiology, vaccine effectiveness, pharmacoeconomics, and safety. The Vaccines Research Area is and has been involved in various randomized clinical trials with GlaxoSmithKline, Novartis, Pfizer, and MSD vaccines. AT is a member of a program funded by Sanofi Pasteur. OL has been an investigator on vaccine studies sponsored by and has received travel support to attend scientific meetings from Sanofi Pasteur and other pharmaceutical companies. Finally, the authors confirm that their competing interests, as previously stated, do not alter their adherence to PLOS ONE policies on sharing data and materials. All other authors declare no conflicts of interest.

Figures

Figure 1
Figure 1. Number of admissions by epidemiological week at each site.
The number of patients enrolled and included in the IVE analysis is shown by epidemiological week at each site for each influenza strain.
Figure 2
Figure 2. Heterogeneity of IVE estimates at each site overall.
Figure 3
Figure 3. Heterogeneity of IVE estimates at each site for each age group.
Figure 4
Figure 4. Heterogeneity of IVE estimates at each site for each strain.
Figure 5
Figure 5. Heterogeneity of IVE estimates for each strain in patients 18–64 years of age.
Figure 6
Figure 6. Heterogeneity of IVE estimates for each strain in patients ≥65 years of age.
See this image and copyright information in PMC

References

    1. Monto AS, Ansaldi F, Aspinall R, McElhaney JE, Montano LF, et al. (2009) Influenza control in the 21st century: Optimizing protection of older adults. Vaccine 27: 5043–5053. - PubMed
    1. Osterholm MT, Kelley NS, Sommer A, Belongia EA (2012) Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis 12: 36–44. - PubMed
    1. Bragstad K, Emborg H, Fischer TK, Voldstedlund M, Gubbels S, et al... (2013) Low vaccine effectiveness against influenza A(H3N2) virus among elderly people in Denmark in 2012/13–a rapid epidemiological and virological assessment. Euro Surveill 18. - PubMed
    1. Kelly HA, Sullivan SG, Grant KA, Fielding JE (2013) Moderate influenza vaccine effectiveness with variable effectiveness by match between circulating and vaccine strains in Australian adults aged 20–64 years, 2007–2011. Influenza Other Respi Viruses 7: 729–737. - PMC - PubMed
    1. McMenamin J, Andrews N, Robertson C, Fleming D, Durnall H, et al... (2013) Effectiveness of seasonal 2012/13 vaccine in preventing laboratory-confirmed influenza infection in primary care in the United Kingdom: mid-season analysis 2012/13. Euro Surveill 18. - PubMed

Publication types

Substances